EXPEREO
16.5.2023 08:01:34 CEST | Business Wire | Press release
Expereo, the leading global managed services provider specialising in intelligent internet connectivity, today unveils its new brand identity reflecting the redefined strategy focused solely on the global future of connectivity and how to help multi-national enterprises succeed in the hyperconnected world of the future. Expereo’s new look and feel represents a commitment to innovation and the company’s role and purpose of bridging the gap to make the internet better for businesses as they move faster to the future.
A dynamic global economy driven by information and digital technologies is accelerating the push toward a hyperconnected future. To win in this rapidly evolving business environment, the digital enterprise of today needs a powerful, flexible enterprise network built for the future – one that is capable of connecting people, places, cloud, and things, wherever in the world organisations are doing business.
However, research recently commissioned by Expereo with 650 CIOs in global organisations with over £500 million turnover, found that businesses’ ambitions to work globally are hindered by many technology-related challenges. The research to be fully launched in June, found that nearly half of CIOs (46%) said that their organisation is planning to deliver global growth in the next 12 months by expanding into new markets, and that 47% of respondents identified establishing and managing global connectivity as the most critical factor in ensuring success when it comes to that global expansion. However, over a third (37%) said that effectively establishing connectivity in new regions is one of the major challenges in their role and in fact their organisation.
Ben Elms, Chief Revenue Officer, Expereo commented:
“Global connectivity is critical to business growth but evidently many organisations are still unnecessarily struggling. Our refreshed brand identity and go-to-market strategy reflects how we see our partnership with our customers, suppliers and partners – a bridge to move our business to the future and in turn help to accelerate our customers' businesses to the future. We’ve helped global businesses adapt to dynamic market conditions and changing technology trends for over 19 years. In today’s world our knowledge and experience is more important than ever as companies look to de-risk their digital transformation.
We hope that our own journey of fast global growth and transformation shows that we understand the challenges enterprises face, and reinforces our position as a trusted partner; one who not only has a comprehensive solution set and continues to innovate, but whose global footprint, proven track record and total customer-centric approach makes us an obvious choice for any global enterprise seeking a flexible, agile, secure and high-performing internet connectivity solution.”
For more information on Expereo’s story and what this means for global organisations with growth ambitions, visit: https://uk.linkedin.com/company/expereo
About Expereo
Expereo is a leading global provider of managed network solutions including, Global Internet, SD-WAN/SASE, and Enhanced Internet. With an extensive global reach, Expereo is the trusted partner of 30% of Fortune 500 companies. It powers enterprise and government sites in more than 190 countries, helping customers improve productivity and empowering their networks and cloud services with the agility, flexibility and value of the Internet, with optimal network performance.
Expereo was acquired in Feb 2021, by Vitruvian Partners. The international growth capital and buyout firm, acquired a majority shareholding from leading European private equity firm, Seven2.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom